To the editor: We read with interest the recent article by Hsu et al[1][1] that reported that the immunomodulatory properties of lenalidomide were lost when used in combination with dexamethasone in multiple myeloma patients. Specifically, they reported reduced natural killer (NK) activity caused
No takes yet. Share an insight, caveat, or question.
Carter et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: